Boldenone and LGD-4033 Interaction: Synergistic | Peptide Database

Join others researching Liothyronine (T3) — share findings, ask questions, and learn from real experiences Liothyronine (T3) is the biologically active form of thyroid hormone, responsible for regulating basal metabolic rate, thermogenesis, protein synthesis, and cellular energy metabolism throughout the body. Unlike levothyroxine (T4), which serves primarily as a prohormone requiring peripheral conversion by deiodinase enzymes, T3 acts directly on nuclear thyroid hormone receptors to exert its metabolic effects. It has been FDA-approved since the 1950s for the treatment of hypothyroidism, myxedema coma, and as a diagnostic agent in thyroid suppression tests. Pharmaceutical T3 is available as Cytomel (brand) and generic liothyronine sodium tablets. In performance and biohacking contexts, T3 is widely used during cutting phases to accelerate fat loss by directly upregulating metabolic rate, and by individuals seeking metabolic optimization when peripheral T4-to-T3 conversion is impaired due to caloric restriction, stress, or other factors. Liothyronine enters target cells via monocarboxylate transporter 8 (MCT8) and other thyroid hormone transporters, then binds to nuclear thyroid hormone receptors (primarily TR-beta in metabolic tissues and TR-alpha in cardiac tissue). The T3-receptor complex forms heterodimers with retinoid X receptors (RXR) and binds to thyroid hormone response elements (TREs) on DNA, directly modulating gene transcription. This increases expression of Na+/K+ ATPase (driving cellular energy expenditure), uncoupling proteins (UCP1 in brown adipose tissue, promoting thermogenesis), and enzymes involved in fatty acid oxidation, gluconeogenesis, and protein turnover. T3 also upregulates beta-adrenergic receptor density, which amplifies catecholamine sensitivity and contributes to increased heart rate, lipolysis, and thermogenesis. At physiological doses, T3 supports healthy metabolism; at supraphysiological doses, it shifts the body into a catabolic state where both fat and lean tissue can be catabolized for energy.

Join others researching Raloxifene — share findings, ask questions, and learn from real experiences Raloxifene is a second-generation selective estrogen receptor modulator (SERM) FDA-approved for the prevention and treatment of postmenopausal osteoporosis and for breast cancer risk reduction. Unlike tamoxifen, raloxifene has a benzothiophene core rather than a triphenylethylene backbone, giving it a distinct tissue-selectivity profile. In performance enhancement contexts, raloxifene is widely regarded as the preferred SERM for gynecomastia reversal because of its stronger antagonist activity at breast tissue estrogen receptors with fewer off-target effects. However, raloxifene is not an effective standalone post-cycle therapy drug because it does not stimulate the hypothalamic-pituitary-testicular axis as robustly as tamoxifen or enclomiphene. Its weaker antagonism at hypothalamic estrogen receptors means it produces comparatively modest elevations in LH and FSH, making it poorly suited for driving testosterone recovery after anabolic steroid cycles. Raloxifene carries a lower risk of endometrial stimulation than tamoxifen, as it acts as an estrogen antagonist rather than a partial agonist in uterine tissue. Raloxifene binds to both estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta), producing tissue-dependent agonist or antagonist effects determined by the local complement of coactivator and corepressor proteins. In breast tissue, raloxifene functions as a potent estrogen antagonist, blocking estradiol-mediated proliferative signaling with high selectivity. This strong breast-tissue antagonism underlies its effectiveness for gynecomastia treatment and breast cancer risk reduction. In bone, raloxifene acts as an estrogen agonist, maintaining bone mineral density by inhibiting osteoclast-mediated resorption. Critically, raloxifene is a weaker antagonist at hypothalamic estrogen receptors compared to tamoxifen, which means it produces less disruption of estrogen-driven negative feedback on GnRH secretion. The result is a more modest increase in LH and FSH compared to tamoxifen, limiting its utility as a standalone PCT agent. In the uterus, raloxifene does not exhibit the partial agonist activity seen with tamoxifen, which translates to a substantially lower risk of endometrial hyperplasia and endometrial cancer with long-term use. Raloxifene is metabolized primarily through glucuronidation rather than CYP450-dependent oxidation, which reduces the potential for drug-drug interactions compared to tamoxifen.